Research Progress of Immunotherapy for Non-small Cell Lung Cancer
with Drive Gene Mutation / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 201-206, 2022.
Article
ي Zh
| WPRIM
| ID: wpr-928798
المكتبة المسؤولة:
WPRO
ABSTRACT
Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has "driver gene mutations" and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after treatment. Previous studies demonstrated that immune checkpoint inhibitor could improve the prognosis of advanced-stage NSCLC and prolong the survival time. However, the efficacy of immune therapy varies in NSCLC patients with different immune and molecular features. The efficacy of immune therapy was controversial in NSCLC patients with driver gene mutation. The present review will summarize the immune characteristics of NSCLC patients with driver mutation and the directions of immunotherapy for patients with driver mutation.
.
Key words
النص الكامل:
1
الفهرس:
WPRIM
الموضوع الرئيسي:
Carcinoma, Non-Small-Cell Lung
/
Molecular Targeted Therapy
/
Immunotherapy
/
Lung Neoplasms
/
Mutation
نوع الدراسة:
Prognostic_studies
المحددات:
Humans
اللغة:
Zh
مجلة:
Chinese Journal of Lung Cancer
السنة:
2022
نوع:
Article